Scilex Holding Company entered into a Promissory Note establishing an uncommitted revolving line of credit with Vivasor, Inc., allowing Vivasor to borrow up to $20 million. The facility carries a 5% annual interest rate and matures in 120 months from August 8, 2026. Scilex has no obligation to fund any drawdowns, which may be made in cash, Scilex securities, or Datavault AI shares at its sole discretion. Dr. Henry Ji serves as CEO of both companies. This transaction represents a related-party lending arrangement within the biotechnology and healthcare sector.

Scilex Holding Company entered into a stock repurchase agreement with Vivasor Holding Company on July 18, 2026, to sell 6,101,468 shares of Series A-1 Preferred Stock and 355,919 shares of Series A-2 Preferred Stock. The aggregate purchase price is $11,999,762.28, payable in five tranches over several months through June 30, 2027. Scilex Holding Company is a pharmaceutical company focused on developing and commercializing specialized medicine.